Program
IBI311
A development code. Also written as “IBI311 (20 mg)”, “IBI311 (3-20 mg)” and “IBI311 (10 mg)”.
Its studies are mostly in Graves Ophthalmopathy, led by Innovent Biologics.
Furthest: phase 3, since Mar 6, 20235 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 51 open or running | phase 3since Mar 6, 2023 | Jul 15, 2022 | Dec 31, 2026phase 3 · NCT07113262 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 15, 2022First study: phase 1 study in HealthyFirst studyNCT05480579 · 28 enrolled · China
- Mar 6, 2023Phase 3 study in Graves OphthalmopathyNCT05795621 · 115 enrolled · China
- Oct 19, 2023Phase 3 study in Graves OphthalmopathyNCT06126783 · 91 enrolled · China
- Jul 24, 2024Phase 2 study in Graves OphthalmopathyNCT06525506 · 38 enrolled · China
- Jul 28, 2025Phase 3 study in Graves OphthalmopathyNCT07113262 · 111 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Graves OphthalmopathyNCT07113262
TargetBeta
IGF1R →read by rule
“IBI311 is a fully human anti-IGF-1R mAb.”study text, by rule · the study
Other programs on IGF1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| teprotumumabrule | Amgen | phase 4 | 18 |
| veligrotugrule | viridian-therapeutics-inc | phase 4 | 7 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| MHB018Arule | Minghui Pharmaceutical | phase 3 | 6 |
| IBI3031rule | Innovent Biologics | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07113262Graves Ophthalmopathy · China | 3 | Recruiting | Dec 31, 2026 | 111 |
| NCT06525506Graves Ophthalmopathy · China | 2 | Completed | Jan 9, 2025 | 38 |
| NCT06126783Graves Ophthalmopathy · China | 3 | Completed | Sep 23, 2025 | 91 |
| NCT05795621Graves Ophthalmopathy · China | 3 | Completed | Dec 20, 2023 | 115 |
| NCT05480579Healthy · China | 1 | Completed | Nov 23, 2022 | 28 |
How it is read
Names in the registry
- “IBI311”, 7 entries
- “IBI311 (20 mg)”, 1 entry
- “IBI311 (3-20 mg)”, 1 entry
- “IBI311 (10 mg)”, 1 entry
- “IBI311 (3-10mg/kg)”, 1 entry
Codes read as this program: IBI311.
Conditions, from the studies’ own filings
- Graves Ophthalmopathy, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.